Condition: Head and Neck Cancers- Squamous Cell · Head and Neck Cancer Metastatic · Recurrent Head and Neck Squamous Cell Carcinoma · Sponsor: National Taiwan University Hospital
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different treatment modalities and drugs. The main questions it aims to answer are: 1. Investigators plan to correlate circulating tumor cells (CTC), circulating tumor emboli (CTM), and the composition of NK cells in CTM with clinical outcomes and establish their association with patient prognosis. 2. Investigators plan to understand the composition of NK cells and the immune cell components within CTM, and correlate these findings with treatment efficacy. Patients with recurrent/metastatic head and neck cancer will be included after informed consent and investigators will collect blood samples for analysis from them under the treatment provided by their primary care physicians.
This description comes directly from the study's public registry record.
Hsu Wu, M.D. · +886-3-5326151 · G04187@hch.gov.tw
Wei-Chen Lu, M.D. · +886-5-5323911
Always discuss trial participation with your own doctor first.
| National Taiwan University HsinChu Branch | Zhubei, HsinChu County, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06678724